Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

1Q Revenues: $16.1 billion (flat)

1Q Earnings: $3.9 billion (+12%)

Comments: Pharma sales were $6.3 billion, up 1%, with a slight negative impact from currency rates. Consumer sales dropped 2% to $3.6 billion, as the company continues to struggle with product shortages generated by its quality problems. Remicade sales were up 18% to $1.5 billion and Stelara sales rose 33% to $221 million, but Levaquin sales plummeted 93% from $434 million to $29 million. Doxil sales also collapsed, dropping from $139 million to $24 million. Velcade sales rose 26% to $353 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters